iCRT3 | 901751-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: iCRT3
• 英文别名: 2-(((2-(4-Ethylphenyl)-5-methyloxazol-4-yl)methyl)thio)-N-phenethylacetamide；2-[[2-(4-ethylphenyl)-5-methyl-1,3-oxazol-4-yl]methylsulfanyl]-N-(2-phenylethyl)acetamide
• CAS: 901751-47-1
• 化学式: C₂₃H₂₆N₂O₂S
• mdl: MFCD14766288
• 分子量: 394.538
• InChiKey: QTDYVSIBWGVBKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  80.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS<br/>[FR] ANALOGUES SUBSTITUÉS DE 1H-INDAZOL-1-OL EN TANT QU'INHIBITEURS D'INTERACTIONS PROTÉINE-PROTÉINE BÊTA-CATÉNINE/TCF
  申请人：UNIV UTAH RES FOUND

  公开号：WO2013120045A1

  公开（公告）日：2013-08-15

  In one aspect, the invention relates to substituted lH-benzo[d][l,2,3]triazol-l-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with β-catenin/Tcf protein- protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的1H-苯并[d][1,2,3]三唑-1-醇类似物，其衍生物以及相关化合物；制备这些化合物的合成方法；包括这些化合物的药物组合物；以及利用这些化合物和组合物治疗与β-连环蛋白/Tcf蛋白相互作用功能障碍相关的疾病，例如各种肿瘤和癌症的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不打算限制本发明。
• SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS
  申请人：UNIVERSITY OF UTAH RESEARCH FOUNDATION

  公开号：US20150025114A1

  公开（公告）日：2015-01-22

  In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with β-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明在某一方面涉及取代的1H-苯并[d][1,2,3]三唑-1-醇类似物，其衍生物和相关化合物；制备该化合物的合成方法；包含该化合物的药物组合物；以及使用该化合物和组合物治疗与β-catenin/Tcf蛋白质相互作用功能障碍相关的疾病，例如各种肿瘤和癌症的方法。本摘要旨在作为特定领域搜索的工具，不限制本发明。
• Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions
  申请人：University of Utah Research Foundation

  公开号：US10273246B2

  公开（公告）日：2019-04-30

  In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3′,4′:5,6]pyrazino[2,3-b]indole analogs, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a β-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，本发明涉及取代的5H-[1,2,5]噁二唑并[3′,4′:5,6]吡嗪并[2,3-b]吲哚类似物、其衍生物和相关化合物；制造这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与β-catenin/细胞因子相互作用功能障碍相关的疾病，例如各种肿瘤和癌症的方法。本摘要旨在作为一种扫描工具，用于特定技术领域的检索，并非对本发明的限制。
• Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types
  申请人：ONCONOSTIC TECHNOLOGIES, INC.

  公开号：US10570458B2

  公开（公告）日：2020-02-25

  In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of FOXC1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided. In other embodiments, methods for diagnosing metastatic breast cancer using the expression ratio of FOXC1/FOXA1 in a population of breast cancer tumor cells are provided. The methods also entail administering a treatment for metastatic breast cancer if the expression ratio of FOXC1/FOXA1 in the population of breast cancer tumor cells is elevated as compared to a control. Other embodiments provide methods for treating breast cancer with a proteasome inhibitor alone or in combination with a Wnt inhibitor in subjects with tumor cells expressing FOXC1 in a subject.

  在一个实施方案中，提供了对乳腺癌肿瘤进行治疗分类的方法，其中分类是通过检测 FOXC1 的表达水平来确定的。在其他实施方案中，提供了预测基底样乳腺癌预后的方法和治疗基底样乳腺癌的方法。在其他实施方案中，提供了利用乳腺癌肿瘤细胞群中 FOXC1/FOXA1 的表达比诊断转移性乳腺癌的方法。如果乳腺癌肿瘤细胞群中 FOXC1/FOXA1 的表达比与对照组相比升高，这些方法还需要对转移性乳腺癌进行治疗。其他实施方案提供了在肿瘤细胞表达FOXC1的受试者中单独使用蛋白酶体抑制剂或与Wnt抑制剂联合使用蛋白酶体抑制剂治疗乳腺癌的方法。
• Methods for treating diseases related to the wnt pathway
  申请人：Sandia Corporation

  公开号：US10624949B1

  公开（公告）日：2020-04-21

  The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

  本发明涉及治疗疾病的方法，其中疾病是由 Wnt 信号通路失调引起的。在某些情况下，可以通过施用抑制 Wnt 通路的化合物来治疗疾病。在其他情况下，该方法可选地包括进行全基因组筛选，以确定导致疾病状态降低的一个或多个基因，然后确定这些基因参与Wnt信号通路。